High-throughput Tissue Microarray Analysis of C-myc Activation in Chronic Liver Diseases and Hepatocellular Carcinoma
Overview
Affiliations
Amplification of 8q23-qter is common in human hepatocellular carcinoma (HCC). c-myc, an oncogene located on 8q24, may be important in hepatocarcinogenesis. The present study aimed to evaluate c-myc activation in hepatocarcinogenesis and its clinicopathological significance. High-throughput analysis of c-myc gene amplification and expression using dual-color fluorescence in situ hybridization and immunohistochemistry was performed on tissue microarrays consisting of 458 liver samples comprising HCCs, nontumorous livers and normal livers. HCCs demonstrated frequent c-myc amplification (30% when corrected for chromosome 8 aneusomy). In contrast, the noncancerous livers, which were mostly chronic hepatitis and cirrhosis, exhibited no c-myc amplification. Despite c-myc amplification, the HCCs exhibited less nuclear c-myc expression than the livers with chronic liver diseases and normal livers (P <0.001 and 0.004, respectively). The HCCs also had less cytoplasmic c-myc staining than the livers with chronic liver diseases (P = 0.002). Despite their absence of c-myc amplification, however, the livers with chronic disease had significantly increased expression of both nuclear and cytoplasmic c-myc protein compared with normal livers (P = 0.015 and 0.009, respectively). Clinicopathologically, the reduction in nuclear c-myc was more marked in HCCs with venous permeation and absence of tumor encapsulation (P = 0.013 and 0.021, respectively), whereas HCCs with cytoplasmic c-myc were positively associated with larger tumor size (P = 0.027). There was no significant association between c-myc amplification and protein expression levels in HCC. Our results suggest that overexpression of c-myc in chronic liver diseases may play an important role in the predisposition to hepatocarcinogenesis. Although c-myc was amplified in HCC, there appears to be a tight regulation by independent pathways of c-myc activation in hepatocarcinogenesis.
Tiu Y, Gong L, Zhang Y, Luo J, Yang Y, Tang Y Cancer Gene Ther. 2022; 29(11):1720-1730.
PMID: 35760898 DOI: 10.1038/s41417-022-00490-1.
MiR-138 is a potent regulator of the heterogenous MYC transcript population in cancers.
Desi N, Teh V, Tong Q, Lim C, Tabatabaeian H, Chew X Oncogene. 2021; 41(8):1178-1189.
PMID: 34937878 PMC: 8856960. DOI: 10.1038/s41388-021-02084-x.
Jiang X, Liu Y, Wang G, Yao Y, Mei C, Wu X Am J Cancer Res. 2020; 10(8):2355-2370.
PMID: 32905514 PMC: 7471371.
Kovi R, Bhusari S, Mav D, Shah R, Ton T, Hoenerhoff M Arch Toxicol. 2019; 93(8):2219-2235.
PMID: 31278416 PMC: 6830449. DOI: 10.1007/s00204-019-02505-7.
Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M J Immunother Cancer. 2018; 6(1):125.
PMID: 30458889 PMC: 6247677. DOI: 10.1186/s40425-018-0431-x.